Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Trill Impact in connection with the acquisition of ID North AB
Mandate

Vinge advises Trill Impact in connection with the acquisition of ID North AB

October 25, 2021 Corporate Commercial IT, Telecommunications and Outsourcing Intellectual Property M&A

Vinge advises Trill Impact in connection with the acquisition of ID North AB (”ID North”).

ID North operates within Identity Access Management and cyber security providing IT consulting services, resale and in-house development of IT products with its base in Stockholm. With an ambition to build a leading group that addresses the increasing need for cybersecurity services, the acquisition of ID North comprises one of two platform investments to the new group called European ID Security.

Vinge’s team consisted of Christina Kokko together with Karl Klackenberg, Desirée Hagenfeldt and Nina Gransäter (M&A), Åsa Gotthardsson and Carl Östlund (Employment), Sofia Bergenstråhle (IP), Alva Hägglund (Corporate Commercial), Karl-Hugo Engdahl (IT and GDPR), Tove Lövgren Frisk (Compliance) and Sara Dahlros Sköld (VDR assistant).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025